Metastatic Bone Disease

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 793-810

  Body, Jean Jacques ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34948823159     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50049-2     Document Type: Chapter

References (130)

1. Galasko C.S.B. Skeletal metastases. Clin. Orthop. Rel. Res. 1986, 210:18-30.
2. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer 1987, 55:61-66.
3. Kamby C., Vejborg I., Daugaard S., Guldhammer B., Dirksen H., Rossing N., Mouridsen H.T. Clinical and radio logic characteristics of bone metastases in breast cancer. Cancer 1987, 60:2524-2531.
4. Body J.J. Bisphosphonates in the treatment of metastatic breast cancer. J. Mam. Gland Biol. Neoplasia 2001, 6:477-485.
5. Body J.J., Lossignol D., Ronson A. The concept of rehabilitation of cancer patients. Curr. Opin. Oncol. 1997, 9:332-340.
6. Elte J.W.F., Bijvoet O.L.M., Cleton F.J., van Oosterom A.T., Sleeboom H.P. Osteolytic bone metastases in breast carcinoma: pathogenesis, morbidity and bisphosphonate treatment. Eur. J. Cancer Clin. Oncol. 1986, 22:493-500.
7. Body J.J. Bone metastases. Handbook of Supportive Care in Cancer 1999, 453-481. Marcel dekker Inc., New York, Basel, Hong Kong. 2nd ed. J. Klastersky, S.C. Schimpff, H.J. Senn (Eds.).
8. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer 2000, 88(12 Suppl):3033-3037.
9. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997, 69:1-18.
10. Sherry M.M., Greco F.A., Johnson D.H., Hainsworth J.D. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am. J. Med. 1986, 81:381-386.
11. Kamby C., Rasmussen B.B., Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br. J. Cancer 1989, 60:252-257.
12. Yamashita K., Koyama H., Inaji H. Prognostic significance of bone metastasis from breast cancer. Clin. Orthop. Rel. Res. 1995, 312:89-94.
13. Rodan G.A. The development and function of the skeleton and bone metastases. Cancer 2003, 97(3 Suppl):726-732.
14. Body J.J. Tumor Bone Diseases and Osteoporosis in Cancer Patients 2000, Marcel Dekker Inc., New York & Basel.
15. Mundy G.R. Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
16. Hofbauer L.C. Osteoprotegerin ligand and osteoprotegerin: novelimplications for osteoclast biology and bone metabolism. Eur. J. Endo. 1999, 141:195-210.
17. Lacroix M., Siwek B., Marie P.J., Body J.J. Production of interkeukin-11 by breast cancer cells. Cancer Lett. 1998, 127:29-35.
18. Goltzman D., Rabbani S.A. Pathogenesis of osteoblastic metastases. Tumor Bone Diseases and Osteoporosis in Cancer Patients 2000, 71-84. Marcel Dekker Inc, New York & Basel. J.J. Body (Ed.).
19. Body J.J. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 2003, 12:S37-S44.
20. Barillé S., Collettes M., Batailles R., Amiots M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995, 86:3151-3159.
21. Body J.J., Mancini I. Bisphosphonates for cancer patients: why, how and when?. Supp. Care Cancer 2002, 10:399-407.
22. Body J.J., Diel I.J., Bell R., Pecherstorfer M., Lichinitzer M.R., Lazarev A.F., Tripathy D., Bergström B. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004, 111:306-312.
23. Gold R.I., Seeger L.L., Bassett L.W., Steckel R.J. An integrated approach to the evaluation of metastatic bone disease. Radiol. Clin. North Am. 1990, 28:471-483.
24. Jacobson A.F., Cronin E.B., Stomper P.C., Kaplan W.D. Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions. Radiology 1990, 175:229-232.
25. Coleman R.E., Mashiter G., Whitaker K.B., Moss D.W., Rubens R.D., Fogelman I. Bone scan flare predicts successful systemic therapy for boen metastases. J. Nucl. Med. 1988, 29:1354-1359.
26. Pecherstorfer M., Zimmer-Roth I., Schilling T., Woitge H.W., Schmidt H., Baurngartner G., Thiebaud D., Ludwig H., Seibel M.J. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J. Clin. Endocrinol. Metab. 1995, 80:97-103.
27. Body J.J., Delmas P.D. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J. Clin. Endocrinol. Metab. 1992, 74:471-475.
28. Body J.J., Dumon J.C., Piccart M., Ford J. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J. Bone Miner. Res. 1995, 10:1191-1196.
29. Juraschek M., Seibel M.J., Woitge H.W., Krempien B., Bauss F. Association between histomorphometry and biochemical markers of bone tumover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysis. Bone 2000, 26:475-483.
30. Blumsohn A., Herrington K., Hannon R.A., Shao P., Eyre D.R., Eastell R. The effect of calcium supplementation on the circadian rhythm of bone resorption. J. Clin. Endocrinol. Metab. 1994, 79:730-735.
31. Fermo I., Arcelloni C., Casari E., Paroni R. Urine pyridinium cross-links determination by Beckman Cross Links kit. Clin. Chem. 1997, 43:2186-2187.
32. Garnero P., Gineyts E., Arbault P., Christiansen C., Delmas P.D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound crosslinks expression. J. Bone Miner. Res. 1995, 10:641-649.
33. Woitge H.W., Pecherstorfer M., Li Y., Keck A.V., Horn E., Ziegler R., Seibel M.J. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J. Bone Miner Res. 1999, 14:792-801.
34. Coleman R.E., Purohit O.P., Vinholes J.J., Zekri J. High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997, 80(8 Suppl):1686-1690.
35. Hassager C., Jensen L.T., Podenphant J., Thomsen K., Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type 1 collagen in serum as a marker of bone resorption: the effect of Nandrolone decanoate and hormone replacement therapy. Calcif. Tissue Int. 1994, 54:30-33.
36. Orwoll E.S., Bell N.H., Nanes M.S., Flessland K.A., Pettinger M.B., Mallinak N.J., Cain D.F. Collagen N-telopeptide excretion in men: the effects of age and intrasubject variability. J. Clin. Endocrinol. Metab. 1998, 83:3930-3935.
37. Rosen H.N., Moses A.C., Garber J., Iloputaife I.D., Ross D.S., Lee S.L., Greenspan S.L. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif. Tissue Int. 2000, 66:100-103.
38. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Vaananen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J. Bone Miner. Res. 2000, 15:1337-1345.
39. Seibel M.J., Woitge H.W., Pecherstorfer M., Karmatschek M., Horn E., Ludwig H., Armbruster F.P., Ziegler R. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J. Clin. Endocrinol. Metab. 1996, 81:3289-3298.
40. Seibel M.J., Lang M., Geilenkeuser W.J. Interlaboratory variation of biochemical markers of bone turnover. Clin. Chem. 2001, 47:1443-1445.
41. Body J.J., Coleman R.E., Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat. Rev. 1996, 22:265-287.
42. Stewart A.F., Vignery A., Silverglate A., Ravin N.D., Livolsi V., Broadus A.E., Baron R. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J. Clin. Endocrinol. Metab. 1982, 55:219-227.
43. Dumon J.C., Wantier H., Mathieu F., Mantia M., Body J.J. Technical and clinical validation of a new immunoradiometric assay for human osteocalcin. Eur. J. Endocrinol. 1996, 135:231-237.
44. Dumon J.C., Body J.J. Circulating osteocalcin in hypercalcemic cancer patients-A comparative evaluation of two immunoassays. Diagnostic Oncol. 1995, 4:170-173.
45. Nakayama K., Fukumoto S., Takeda S., Takeuchi Y., Ishikawa T., Miura M., Hata K., Hane M., Tamura Y., Tanaka Y., Kitaoka M., Obara T., Ogata E., Matsumoto T. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J. Clin. Endocrinol. Metab. 1996, 81:607-611.
46. Body J.J., Dumon J.C., Blocklet D., Darte C. The bone isoenzyme of alkaline phosphatase in hypercalcaemic cancer patients. Eur. J. Cancer. 1997, 33:1578-1582.
47. Sato K., Yamakawa Y., Shizume K., Satoh T., Nohtomi K., Demura H., Akatsu T., Nagata N., Kasahara T., Ohkawa H., Ohsumi K. Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors. J. Bone Miner. Res. 1993, 8:849-860.
48. Endres D.B., Villanueva R., Sharp C.F., Singer F.R. Immunochemiluminometric and immunoradiometric determin ations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia, and hypoparathyroidism. Clin. Chem. 1991, 37:162-168.
49. Walls J., Ratcliffe W.A., Howell A., Bundred N.J. Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations. Clin. Endocrinol. 1994, 41:407-413.
50. Body J.J., Dumon J.C., Thirion M., Cleeren A. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy. J. Bone Miner. Res. 1993, 8:701-706.
51. Grill V., Ho P., Body J.J., Johanson N., Lee S.C., Kukreja S.C., Moseley J.M., Martin T.J. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J. Clin. Endocrinol. Metab. 1991, 73:1309-1315.
52. Burtis W.J. Parathyroid hormone-related protein: structure, function and measurement. Clin. Chem. 1992, 38:2171-2183.
53. Body J.J., Dumon J.C., Seraj F., Cleeren A. Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia. J. Clin. Endocrinol. Metab. 1992, 74:1385-1388.
54. Berruti A., Dogliotti L., Gorzegno G., Torta M., Tampellini M., Tucci M., Cerutti S., Frezet M.M., Stivanello M., Sacchetto G., Angeli A. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin. Chem. 1999, 45:1240-1247.
55. Woitge H.W., Seibel M.J., Ziegler R. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorders or metabolic bone diseases. Clin. Chem. 1996, 42:1796-1804.
56. Marchei P., Santini D., Bianco V., Chiodini S., Reale M.G., Simeoni F., Marchei G.G., Vecchione A. Serum Ostase in the follow-up of breast cancer patients. Anticancer Res. 1995, 15:2217-2222.
57. Van Hoof V.O., Van Oosterom A.T., Lepoutre L.G., De Broe M.E. Alkaline phosphatase isoenzyme patterns in malignant disease. Clin. Chem. 1992, 38:2546-2551.
58. Zaninotto M., Secchiero S., Rubin D. Serum bone alkaline phosphatase in the follow-up of skeletal metastases. Anticancer Res. 1995, 15:2223-2228.
59. Berruti A., Piovesan A., Torta M., Raucci C.A., Gorzegno G., Paccotti P., Dogliotti L., Angeli A. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br. J. Cancer 1996, 73:1581-1587.
60. Cooper E.H., Whelan P., Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994, 25:236-242.
61. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., Delmas P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 2000, 82:858-864.
62. Wolff J.M., Itlel T., Boeckmann W., Reinike T., Habib F.K., Jakse G. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Eur. Urol. 1996, 30:302-306.
63. Lorente J.A., Morote J., Raventos C., Encabo G., Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J. Urology 1996, 155:1348-1351.
64. Woitge H.W., Horn E., Keck A.V., Auler B., Seibel M.J., Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin. Chem. 2001, 47:686-693.
65. Alexandrakis M.G., Passam F.H., Malliaraki N., Katachanakis C., Kyriakou D.S., Margioris A.N. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin. Chim. Acta. 2002, 325:51-57.
66. Body J.J., Cleeren A., Pot M., Borkowski A. Serum osteocalcin (BGP) in tumor-associated hypercalcemia. J. Bone Miner. Res. 1986, 1:523-527.
67. Kamby C., Egsmose C., Soletormos G., Dombernowsky P. The diagnostic and prognostic value of serum bone GLA protein (osteocalcin) in patients with recurrent breast cancer. Scand. J. Clin. Lab. Invest. 1993, 53:439-446.
68. Shih W.J., Wierzbinski B., Collins J., Magoun S., Chen I.W., Ryo U.Y. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements. J. Nucl. Med. 1990, 31:1486-1489.
69. Coleman R.E., Mashiter G., Fogelman I., Rubens R.D. Osteocalcin: a marker of metastatic bone disease. Eur. J. Cancer 1988, 24:1211-1217.
70. Bataille R., Delmas P.D., Chappard D., Sany J. Abnormal serum bone Gla protein levels in multiple myeloma. Cancer 1990, 66:167-172.
71. Mejjad O., Le Loët X., Basuyau J.P., Ménard J.F., Jego P., Grisot C., Darangon A., Grosbois B., Euller-Ziegler L., Monconduit M. Osteocalcin is not a marker of progress in multiple myeloma. Eur. J. Hematol. 1996, 56:30-34. le Groupe d'Etude et de Recherche sur le Myélome (GERM).
72. Burlina A., Rubin D., Secchiero S., Sciacovelli L., Zaninotto M., Plebani M. Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin. Chim. Acta 1994, 226:151-158.
73. Ebeling P.R., Peterson J.M., Riggs B.L. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J. Bone Miner. Res. 1992, 7:1243-1250.
74. Nakashima J., Sumitomo M., Miyajima A., Jitsukawa S., Saito S., Tachibana M., Murai M. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J. Urol. 1997, 157:1736-1739.
75. Brown J.M., Corey E., Lee Z.D., True L.D., Yun T.J., Tondravi M., Vessella R.L. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001, 57:611-616.
76. Jung K., Stephan C., Semjonow A., Lein M., Schnorr D., Loening S.A. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligend as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J. Urol. 2003, 170:2302-2305.
77. Jung K., Lein M., Stephan C., Von Hosslin K., Semjonow A., Sinha P., Loening S.A., Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with boee metastatic spread: diagnostic and prognostic implications. Int. J. Cancer 2004, 111:783-791.
78. Vinholes J., Coleman R., Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat. Rev. 1996, 22:289-331.
79. Hou M.F., Lin S.B., Yuan S.S., Tsai L.Y., Tsai S.M., Hsieh J.S., Huang T.J. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients. Ann. Clin. Lab. Sci. 2003, 33:55-61.
80. Lipton A., Demers L., Daniloff Y., Curley E., Hamilton C., Harvey H., Witters L., Seaman J., Van der Giessen R., Seyedin S. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin. Chem. 1993, 39:614-618.
81. Demers L.M. Biochemical markers in the management of patients with metastatic bone disease. Clin. Chem. 1999, 45:1131-1132.
82. Demers L.M., Costa L., Chinchilli V.M., Gaydos L., Curley E., Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin. Chem. 1995, 41:1489-1494.
83. Lipton A., Demers L., Curley E., Chinchilli V., Gaydos L., Hortobagyi G., Theriault R., Clemens D., Costa L., Seaman J., Knight R. Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer 1998, 34:2021-2026.
84. Body J.J., Durnon J.C., Gineyts E., Delmas P.D. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br. J. Cancer 1997, 75:408-412.
85. Ju H.S.J., Leung S., Brown B., Stringer M.A., Leigh S., Scherrer C., Shepard K., Jenkins D., Knudsen J., Cannon R. Comparison of analytical performance and biological variability of three bone resorption assays. Clin. Chem. 1997, 43:1570-1576.
86. Robins S.P., Woitge H., Hesley R., Ju J., Seyedin S., Seibel M.J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 1994, 9:1643-1649.
87. Nguyen-Pamart M., Bonneterre J., Hecquet B. Urinary excretion of deoxypyridinoline in patients with breast cancer. Anticancer Res. 1995, 15:1601-1604.
88. Halleen J.M., Alatalo S.L., Janckila A.J., Woitge H.W., Seibel M.J., Vaananen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem. 2001, 47:597-600.
89. Bombardieri E., Martinetti A., Miceli R., Mariani L., Castellani M.R., Seregni E. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?. Eur. J. Nucl. Med. 1997, 24:1349-1355.
90. Houze P., Bellik B., Extra J.M., Bouro F., Bousquet B. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer. Clin. Chim. Acta 1999, 281:77-88.
91. Ali S.M., Demers L.M., Leitzel K., Harvey H.A., Clemens D., Mallinak N., Engle L., Chinchilli V., Costa L., Brady C., Seaman J., Lipton A. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann. Oncol. 2004, 15:455-459.
92. Miyamoto K.K., McSherry S.A., Robins S.P., Besterman J.M., Mohler J.L. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J. Urol. 1994, 151:909-913.
93. Kylmälä T., Tammela T.L.J., Risteli L., Risteli J., Kontturi M., Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br. J. Cancer 1995, 71:1061-1064.
94. Berruti A., Dogliotti L., Bitossi R., Fasolis G., Gorzegno G., Bellina M., Torta M., Porpiglia F., Fontana D., Angeli A. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J. Urol. 2000, 164:1248-1253.
95. Dawson N.A. Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease. Curr. Opin. Urology 2002, 12:413-418.
96. Ross R.W., Small E.J. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J. Urol. 2002, 167:1952-1956.
97. Terpos E., de la Fuente J., Szydlo R., Hatjiharissi E., Biniou N., Meletis J., Yataganas X., Goldman J.M., Rahemtulla A. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int. J. Cancer 2003, 106:455-457.
98. Withold W., Armbruster F.P., Karmatschek M., Reinauer H. Bone sialoprotein in serum of patients with malignant bone diseases. Clin. Chem. 1997, 43:85-91.
99. Woitge H.W., Pecherstorfer M., Horn E., Keck A.V., Diel I.J., Bayer P., Ludwig H., Ziegler R., Seibel M.J. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br. J. Cancer 2001, 84:344-351.
100. Coleman R.E., Whitaker K.D., Moss D.W., Mashiter G., Fogelman I., Rubens R.D. Biochemical monitoring predicts response in bone to systemic treatment. Br. J. Cancer 1988, 58:205-210.
101. Cooper E.H., Forbes M.A., Hancock A.K., Parker D., Laurence V. Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases. Biomed. Pharmacother. 1992, 46:31-36.
102. Luftner D., Richter A., Geppert R., Wernecke K.D., Possinger K. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Anticancer Res. 2003, 23:1017-1026.
103. Koizumi M., Maeda H., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br. J. Cancer 1997, 75:1601-1604.
104. Williams A.T., Shearer M.J., Oyeyi J., Aitchison R.G., Newland A.C., Schey S.A. Serum osteocalcin in the management of myeloma. Eur. J. Cancer 1992, 29A:140-142.
105. Downey S., Walls J., Ratcliffe W.A., Assiri A.M.A., Howell A., Eastell R., Bundred N.O. Pyridinoline excretion can monitor bone metastases in breast cancer. Breast Cancer Res. Treat. 1994, 32:83.
106. Walls J., Assiri A., Howell A., Rogers E., Ratcliffe W.A., Eastell R., Bundred N.J. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. Br. J. Cancer 1999, 80:1265-1270.
107. Vinholes J., Coleman R., Lacombe D., Rose C., Tubiana-Hulin M., Bastit P., Wildiers J., Michel J., Leonard R., Nortier J., Mignolet F., Ford J. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion European Organization for Research and Treatment of Cancer. Br. J. Cancer 1999, 80:221-228.
108. Coleman R.E. Monitoring of bone metastases. Eur. J. Cancer 1998, 34:252-259.
109. Vinholes J., Coleman R., Lacombe D., Mignolet F., Rose C., Leonard R., Nortier J., Tubiana-Hulin M. Assessment of bone response to systemic therapy in an EORTC trial of oral pamidronate. Eur. J. Cancer 1996, 32A(suppl. 2):50. EORTC Breast Group.
110. Costa L., Demers L.M., Gouveia-Oliveira A., Schaller J., Costa E.B., de Moura M.C., Lipton A. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J. Clin. Oncol. 2002, 20:850-856.
111. Brown J.E., Thomson C.S., Ellis S.P., Gutcher S.A., Purohit O.P., Coleman R.E. Bone resorption predicts for skeletal complications in metastatic bone disease. Br. J. Cancer 2003, 89:2031-2037.
112. Brown J.E., Cook R.J., Major P., Lipton A., Saad F., Smith M., Lee K.A., Zheng M., Hei Y.J., Coleman R.E. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 2005, 97:59-69.
113. Clamp A., Danson S., Nguyen H., Cole D., Clemons M. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004, 5:607-616.
114. Ikeda I., Miura T., Kondo I. Pyridinium cross-links as markers of bone metatases in patients with prostate cancer. Br. J. Urol. 1996, 77:102-106.
115. Elooma I., Virkkunen P., Risteli L., Risteli J. Serum concentration of the cross-linked carboxyteminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br. J. Cancer 1992, 66:337-341.
116. Kylmälä T., Tammela T., Risteli L., Risteli J., Taube T., Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur. J. Cancer 1993, 29A:821-825.
117. Abildgaard N., Brixen K., Eriksen E.F., Kristensen J.E., Nielsen J.L., Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004, 89:567-577.
118. Body J.J. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003, 97:859-865.
119. Body J.J. Zoledronic acid: an advance in tumour bone disease and a new hope for osteoporosis. Expert Opin. Pharmacotherapy 2003, 4:567-580.
120. Vinholes J., Guo C.Y., Purohit O.P., Eastell R., Coleman R.E. Randomised double-blind comparison of pamidronate or clodronate for hypercalcemia of malignancy: effects on bone metabolism markers. J. Clin. Oncol. 1997, 15:131-138.
121. Rubinacci A., Melzi R., Zampino M., Soldarini A., Villa I. Total and free deoxypyridinoline after acute osteoclast activity inhibition. Clin. Chem. 1999, 45:1510-1516.
122. Vinholes J.J.F., Purohit O.P., Abbey M.E., Eastell R., Coleman R.E. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann. Oncol. 1997, 8:1243-1250.
123. Engler H., Koeberle D., Thuerlimann B., Senn H.J., Riesen W.F. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of biosphosphonate on pain intensity and progression of malignant bone disease. Clin. Chem. Lab. Med. 1998, 36:879-885.
124. Menssen H.D., Sakalova A., Fontana A., Hermann Z., Boewer C., Facon T., Lichinitser M.R., Singer C.R., Euller-Ziegler L., Wetterwald M., Fiere D., Hrubisko M., Thiel E., Delmas P.D. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J. Clin. Oncol. 2002, 20:2353-2359.
125. Powles T., Paterson S., Kanis J.A., McCloskey E., Ashley S., Tidy A., Rosenqvist K., Smith I., Ottestad L., Legault S., Pajunen M., Nevantaus A., Mannisto E., Suovuori A., Atula S., Nevalainen J., Pylkkanen L. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 2002, 20:3219-3224.
126. Powles T., Paterson A., McCloskey E., Kurkilahti M., Kanis J. Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. Proc ASCO 2004, 23:9. (Abstract 528).
127. Bellahcène A., Kroll M., Liebens F., Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Miner. Res. 1996, 11:665-670.
128. Bellahcène A., Menard S., Bufalino R., Moreau L., Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int. J. Cancer 1996, 69:350-353.
129. Diel I.J., Solomayer E.F., Seibel M.J., Pfeilschifter J., Maisenbacher H., Gollan C., Pecherstorfer M., Conradi R., Kehr G., Boehm E., Armbruster F.P., Bastert G. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin. Cancer. Res. 1999, 5:3914-3919.
130. Seibel M.J., Koeller M., Van der Velden B., Diel I. Markers of bone turnover do not predict bone metastases in breast cancer. Clin. Lab. 2002, 48:583-588.